The Mount Sinai School of Medicine (MSSM) Alzheimer Disease Research Center (ADRC) continues its commitment to characterize, diagnose, and treat individuals with cognitive decline and dementia. The center is committed to finding causes, treatments, and means of preventing the disease, while also minimizing the emotional and economic cost of care. MSSM ADRC is dedicated to the identification of the clinical and biological benchmarks representing clinical and molecular endophenotypes. Our goal is to provide investigators with a wide distribution of: (a) well characterized patients with AD and other dementias, (b) individuals with MCI, a possible prodromal condition to dementia, and (c) healthy elders for research studies We focus on the very elderly and minority populations, and we have planned studies to insure that they are well-represented in our research efforts. We will assist the broadest community of investigators in accessing populations for clinical investigations (including studies to develop novel biomarkers for diagnosis and disease progression) and in conducting clinical trials of new agents. We will collaborate with the Departments of Psychiatry, Neurology, and Neuroscience in order to stimulate cutting-edge science to address the etiology and pathogenesis of AD. The environment and support provided in our last funding period has resulted in actively funded research projects as well as soon to-be-submitted proposals, all of which draw upon material and expertise from the ADRC Cores. This is evidenced in the three new ADRC Projects proposed herein, all of which feature junior investigators as Project Leaders or Co-Leaders. These Projects are highly innovative and highly integrated with each other and share the endophenotyping theme. As a group, the Projects all focus on aspects of the gamma- secretase reaction, the final step in amyloid beta generation. We will provide core resources and scientific environment to insure the growth of research in AD and related disorders. We will maximize the visibility of our center and its staff and activities in order to raise awareness of the disease We propose to continue our efforts to bring new perspectives to the problem of AD by fostering the growth of new junior researchers and recruiting researchers from other specialty areas into AD-related studies.
Alzheimer disease is a devastating disease that robs an individual of his or her intellect and social capacity. The mission of the MSSM ADRC is to understand the disease pathology so that better treatments, cures, and, ultimately, preventatives are possible.
|Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10|
|Warren, Noel A; Voloudakis, Georgios; Yoon, Yonejung et al. (2018) The product of the ?-secretase processing of ephrinB2 regulates VE-cadherin complexes and angiogenesis. Cell Mol Life Sci 75:2813-2826|
|Tsartsalis, Stergios; Xekardaki, Aikaterini; Hof, Patrick R et al. (2018) Early Alzheimer-type lesions in cognitively normal subjects. Neurobiol Aging 62:34-44|
|Ridge, Perry G; Karch, Celeste M; Hsu, Simon et al. (2018) Correction to: Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. Genome Med 10:4|
|Pimenova, Anna A; Raj, Towfique; Goate, Alison M (2018) Untangling Genetic Risk for Alzheimer's Disease. Biol Psychiatry 83:300-310|
|Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307|
|Culverhouse, R C; Saccone, N L; Horton, A C et al. (2018) Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol Psychiatry 23:133-142|
|Edler, Melissa K; Sherwood, Chet C; Meindl, Richard S et al. (2018) Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees. J Comp Neurol 526:2921-2936|
|Mitchell, A C; Javidfar, B; Pothula, V et al. (2018) MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice. Mol Psychiatry 23:123-132|
|Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17|
Showing the most recent 10 out of 555 publications